<DOC>
	<DOC>NCT01220141</DOC>
	<brief_summary>This study is conducted in Europe and Asia. The aim of this observational study is to monitor antibody formation towards the room temperature stable formulation of NovoSeven® (activated recombinant human factor VII).</brief_summary>
	<brief_title>Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosed with congenital haemophilia A or B with inhibitors to factor VIII or factor IX Treated with room temperature stable NovoSeven®</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>